Novel and Emerging Combination Approaches for Advanced/Metastatic RCC
CE Information
0.75 contact hours (0.6 pharmacology)Completion Time
45 minutesAvailable Until
November 28, 2024Posted By
Prime CENavigate
Overview
Specialties
OncologySubspecialties
Nephrology and OncologyClinical Topics
Nephrology and OncologyIntended Audience: Oncologists, NPs, PAs, nurses, and pharmacists who care for patients with RCC
Join us for an exciting discussion by two renowned renal cell carcinoma (RCC) experts as they delve deep into the dynamic world of RCC and provide essential insights into multiple components of evidence-based, guideline-aligned care.
This on-demand video will review the latest clinical safety and efficacy data on combination approaches for frontline treatment of metastatic renal cell, along with applications of current evidence to treatment sequencing after progression on first-line therapy.
Learning Objectives
- Differentiate novel and emerging therapeutic approaches in clear cell renal cell carcinoma (RCC) based on clinical data for their safety and efficacy and placement in treatment
- Evaluate clinical data for safety and efficacy of novel and emerging combination approaches for frontline treatment of advanced/metastatic RCC
- Apply current evidence and guideline recommendations to optimize treatment sequencing after progression on first-line therapy
- Employ evidence-based strategies for managing adverse events associated with novel combination therapies
Speakers
Assistant Professor of Medicine
Harvard Medical School
Director of Clinical Research
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, MA
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Ingram Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
CE Information
This activity offers 0.75 contact hours (0.6 pharmacology) to attendees.
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.75 contact hour (which includes 0.6 hour of pharmacology).
Disclosures
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
-
Bradley A McGregor, MD (Speaker)
Consultant – Astellas, AstraZeneca, Bristol Myers Squibb for Dana Farber Cancer Institute [DFCI], Bristol-Myers Squibb, Calithera, Dendreon, Discloses payment for consulting with Bayer, EMD Serono, Eisai, Exelixis, Genentech, Janssen, Merck, Nektar, Pfizer, Seattle GeneticsThe relationships reported above are related to the following therapeutic area: Hematology-Oncology
Grants / Research Support – Bristol Myers Squibb for Dana Farber Cancer Institute [DFCI], Bristol-Myers Squibb, Calithera, Exelixis, Merck, Pfizer, Seattle Genetics -
Brian I. Rini, MD, FASCO (Speaker)
Advisory Board or Panel – Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Merck, PfizerThe relationships reported above are related to the following therapeutic area: Hematology-Oncology
Consultant – Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Merck, Pfizer
Grants / Research Support – Aveo, Bristol-Myers Squibb, Merck, Pfizer
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Reviewer)
- Abimbola Farinde, PhD, PharmD (Planner)
- Lisa Wakefield, MSN, APRN, FNP-BC (Planner)
All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity